# GS1-144 in Participants With Hepatic Impairment and Healthy Female

> **NCT07491289** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Hepatic Impairment and Healthy Female

## Interventions

- **DRUG:** GS1-144 tablet

## Key facts

- **NCT ID:** NCT07491289
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07491289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07491289, "GS1-144 in Participants With Hepatic Impairment and Healthy Female". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT07491289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*